Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient

Low-grade serous ovarian cancer (LGSOC) is relatively chemoresistant, and no precision therapy is approved for this indication. Despite promising results in phase II trials, MEK inhibitors have failed to show improved progression-free survival in a phase III trial when compared to physician's c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cold Spring Harb Mol Case Stud
Main Authors: Colombo, Ilaria, Garg, Swati, Danesh, Arnavaz, Bruce, Jeffrey, Shaw, Patricia, Tan, Qian, Quevedo, Rene, Braunstein, Marsela, Oza, Amit M., Pugh, Trevor, Lheureux, Stephanie
Format: Artigo
Jezik:Inglês
Izdano: Cold Spring Harbor Laboratory Press 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6913142/
https://ncbi.nlm.nih.gov/pubmed/31836588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/mcs.a004341
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki